| Autor: |
Akinlalu, Alfred, Flaten, Zachariah, Rasuleva, Komila, Md, Saimon Mia, Bauer, Aaron, Elamurugan, Santhalingam, Ejjigu, Nega, Maity, Sudipa, Amara, Arshad, Wu, Min, Xia, Wenjie, Fan, Jia, Guo, Ang, Mathew, Sijo, Sun, Dali |
| Zdroj: |
The Innovation; 20240101, Issue: Preprints |
| Abstrakt: |
Pancreatic adenocarcinoma (PDAC) is one of the most deadly cancers, characterized by extremely limited therapeutic options and a poor prognosis, as it is often diagnosed during late disease stages. Innovative and selective treatments are urgently needed, since current therapies have limited efficacy and significant side effects. Through proteomics analysis of extracellular vesicles, we discovered an imbalanced distribution of amino acids secreted by PDAC tumor cells. Our findings revealed that PDAC cells preferentially excrete proteins with certain preferential amino acids, including isoleucine and histidine, via extracellular vesicles. These amino acids are associated with disease progression and can be targeted to elicit selective toxicity to PDAC tumor cells. Both in vitroand in vivoexperiments demonstrated that supplementation with these specific amino acids effectively eradicated PDAC cells. Mechanistically, we also identified XRN1 as a potential target for these amino acids. The high selectivity of this treatment method allows for specific targeting of tumor metabolism with very low toxicity to normal tissues. Furthermore, we found this treatment approach is easy-to-administer and with sustained tumor-killing effects. Together, our findings reveal that exocytosed amino acids may serve as therapeutic targets for designing treatments of intractable PDAC and potentially offer alternative treatments for other types of cancers. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
